Arcutis Biotherapeutics Balance Sheet Health
Financial Health criteria checks 4/6
Arcutis Biotherapeutics has a total shareholder equity of $156.6M and total debt of $204.6M, which brings its debt-to-equity ratio to 130.6%. Its total assets and total liabilities are $437.4M and $280.7M respectively.
Key information
130.6%
Debt to equity ratio
US$204.61m
Debt
| Interest coverage ratio | n/a |
| Cash | US$330.56m |
| Equity | US$156.64m |
| Total liabilities | US$280.71m |
| Total assets | US$437.35m |
Recent financial health updates
Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?
Jul 17
Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?
May 02Recent updates
Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?
Nov 15Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Business And Shares Still Trailing The Industry
Sep 23Arcutis: Shares Plateau After Early 2024 Gains, But Further Upside Looks Likely
Aug 22Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?
Jul 17Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Popularity With Investors Is Under Threat From Overpricing
Jun 21Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher
May 24Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory
May 20Arcutis Biotherapeutics: Betting Big On Zoryve
May 01New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)
Apr 25Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues
Mar 03Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates
Mar 02Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up
Feb 28Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture
Jan 31Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%
Oct 23Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher
Aug 13Earnings Release: Here's Why Analysts Cut Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target To US$41.57
Aug 11Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?
May 02Financial Position Analysis
Short Term Liabilities: ARQT's short term assets ($423.7M) exceed its short term liabilities ($172.4M).
Long Term Liabilities: ARQT's short term assets ($423.7M) exceed its long term liabilities ($108.3M).
Debt to Equity History and Analysis
Debt Level: ARQT has more cash than its total debt.
Reducing Debt: ARQT's debt to equity ratio has increased from 0% to 130.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ARQT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ARQT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.